fluorouracil and Complication, Postoperative studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

Excerpt	Relevance	Reference
"To compare the efficacy of transconjunctival needling revision with 5-fluorouracil versus medical treatment in glaucomatous eyes with uncontrolled intraocular pressure due to encapsulated bleb after trabeculectomy."	9.17	Early transconjunctival needling revision with 5-fluorouracil versus medical treatment in encapsulated blebs: a 12-month prospective study. ( Susanna, R; Suzuki, R, 2013)
" 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin."	9.09	Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001)
"To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum."	9.09	Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001)
"The aim of this study was to improve the direct results of reconstructive surgery in patients operated on for complicated forms of colorectal cancer, by using 5-fluorouracil in the postoperative period."	8.12	The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer. ( Irimbetov, S; Osombaev, M; Zhakipbekov, S, 2022)
"To investigate the ocular surface changes occurring in eyes with recurrent pterygium post-operatively treated with 5-fluorouracil intralesional injections."	7.91	Ocular surface changes in recurrent pterygium cases post-operatively treated with 5-fluorouracil subconjunctival injections. ( Boto de Los Bueis, A; García Tirado, A; Rivas Jara, L, 2019)
"To examine the effect of mitomycin c and 5-flurouracil on treatment outcomes following Ahmed glaucoma valve implantation."	7.85	Effect of mitomycin c and 5-flurouracil adjuvant therapy on the outcomes of Ahmed glaucoma valve implantation. ( Cui, QN; Han, Y; Hsia, YC; Lin, SC; Mehta, N; Naseri, A; Porco, TC; Rose-Nussbaumer, J; Stamper, RL, 2017)
"This study was designed to investigate whether 5-fluorouracil (5-Fu)-polycaprolactone sustained-release film in Ahmed glaucoma valve implantation inhibits postoperative bleb scarring in rabbit eyes."	7.81	Application of 5-Fluorouracil-Polycaprolactone Sustained-Release Film in Ahmed Glaucoma Valve Implantation Inhibits Postoperative Bleb Scarring in Rabbit Eyes. ( Bi, XZ; Li, CH; Nan, KH; Pan, WH; Ren, ZJ; Song, ZM; Sun, M; Yu, XP, 2015)
"Bevacizumab reduced the spinal epidural fibrosis significantly that developed in rats after laminectomy and 5-Fluorouracil combination had a synergic effect."	7.80	The effect of bevacizumab and 5-Fluorouracil combination on epidural fibrosis in a rat laminectomy model. ( Ercan, S; Firat, U; Kemaloglu, S; Osun, A; Ozkan, U; Samancioglu, A, 2014)
"To determine whether the use of postoperative subconjunctival 5-fluorouracil (5-FU) reduces the risk of trabeculectomy bleb failure after uncomplicated small incisional cataract surgery."	7.76	Use of 5-Fluorouracil injections to reduce the risk of trabeculectomy bleb failure after cataract surgery. ( Salmon, JF; Shahid, H, 2010)
"Although adjunctive postoperative 5-fluorouracil (5-FU) injections are known to improve the success rate of glaucoma surgery, it is still unknown what dose, timing and frequency of application will give the best results with respect to the inhibition of postoperative scarring and intraocular pressure regulation."	7.74	Dose, timing and frequency of subconjunctival 5-fluorouracil injections after glaucoma filtering surgery. ( Bartz-Schmidt, KU; Besch, D; Denk, PO; Grüb, M; Reinthal, EK, 2007)
"To prospectively study the evolution of possible high risk features of conjunctival filtration blebs like avascularity, transconjunctival oozing (TCO), and leaks after mitomycin C (MMC) enhanced glaucoma surgery."	7.73	Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. ( Anand, N; Arora, S; Clowes, M, 2006)
"To observe the effect of the means of subconjunctiva injection with 5-Fluorouracil (5-Fu) and Triamcinolone to treat the membrane on the anterior surface of intraocular lens after traumatic cataract surgery."	7.73	[Combined 5-Fu and triamcinolone to treat the membrane on the anterior surface of intraocular lens after the surgery of traumatic cataract]. ( Chen, L; Xu, D; Ye, K, 2005)
"To investigate the influence of 5-fluorouracil (5-FU) and mitomycin C (MMC) on the postoperative adhesions following strabismus surgery in rabbits."	7.72	Effects of intraoperative sponge mitomycin C and 5-fluorouracil on scar formation following strabismus surgery in rabbits. ( Düzcan, E; Eşme, A; Ozden, S; Tatlipinar, S; Yaylali, V; Yildirim, C, 2004)
"To determine whether 5-fluorouracil is effective in reducing scarring after strabismus surgery we used rectus muscle surgery in experimental animals to compare a single intraoperative dose of 5-fluorouracil with mitomycin C and to compare results in similarly treated controls not receiving these antimetabolites."	7.69	Intraoperative sponge 5-fluorouracil to reduce postoperative scarring in strabismus surgery. ( Evan, AP; Helveston, EM; Mora, JS; Sprunger, DT, 1997)
"Between 2/1991 and 1/1993 twenty-nine eyes of 11 female and 16 male patients with high-risk glaucoma (unsuccessful previous filtering surgery and a high risk of scarring) were treated with subconjunctival injections of 5-Fluorouracil after filtering surgery in the University Eye Hospital Düsseldorf."	7.68	[5-fluorouracil injection treatment after fistulating glaucoma operations]. ( Klüppel, M; Reinhard, T; Sundmacher, R, 1993)
"We studied 105 patients (105 eyes) operated on for glaucoma with adjunctive fluorouracil, who were followed up for 12 to 48 months (mean, 34."	7.68	Late complications after glaucoma filtering surgery with adjunctive 5-fluorouracil. ( Ophir, A; Ticho, U, 1993)
"Twenty-one eyes of 18 patients with uncontrolled glaucoma and intraocular inflammatory disease had glaucoma filtering surgery with postoperative subconjunctival 5-fluorouracil (5-FU)."	7.68	Glaucoma filtering surgery with postoperative 5-fluorouracil in patients with intraocular inflammatory disease. ( Lowder, CY; Meisler, DM; Patitsas, CJ; Rockwood, EJ, 1992)
"The effectiveness of trabeculectomy with adjunctive low-dose 5-fluorouracil (5-FU) as the initial surgical procedure in uncomplicated glaucoma was evaluated retrospectively in a consecutive series of 52 patients (mean follow-up, 18."	7.68	Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. ( Liebmann, JM; Marmor, M; Nunez, J; Ritch, R; Wolner, B, 1991)
"Nine patients (nine eyes) with iridocorneal endothelial (ICE) syndrome underwent trabeculectomy and received postoperative subconjunctival injections of 5-fluorouracil (5-FU) to enhance bleb formation (total 5-FU dose, 30-105 mg; mean, 53."	7.68	5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. ( Cristol, SM; Grajewski, AL; Parrish, RK; Wright, MM, 1991)
"We reviewed the records of 12 eyes of ten adult patients with inflammatory glaucoma who underwent trabeculectomy with the adjuvant use of 5-fluorouracil between January 1986 and January 1989."	7.68	Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. ( Jabs, DA; Jampel, HD; Quigley, HA, 1990)
"5-Fluorouracil (5-FU) was injected subconjunctivally after glaucoma filtering surgery in a pilot study of eyes with poor surgical prognoses."	7.67	5-fluorouracil and glaucoma filtering surgery. II. A pilot study. ( Anderson, DR; Gressel, MG; Heuer, DK; Hodapp, E; Palmberg, PF; Parrish, RK, 1984)
"We show that a 40-mg total dose of subconjunctival 5-fluorouracil after glaucoma filtering surgery can provide a success rate comparable to that demonstrated in prior studies employing a higher dose."	7.67	Low-dose 5-fluorouracil and glaucoma filtration surgery. ( Rabowsky, JH; Ruderman, JM, 1989)
"The effect of 5-fluorouracil (5-FU) subconjunctival injection on the bleb formation and intraocular pressure (IOP) following trabeculectomy was studied in 18 glaucoma patients (20 eyes) with poor surgical prognosis."	7.67	5-Fluorouracil for trabeculectomy in glaucoma. ( Kitazawa, Y; Nakano, Y; Shirato, S; Taniguchi, T; Yamamoto, T, 1987)
"We studied four patients who, having received postoperative 5-fluorouracil after glaucoma filtering operations, developed serious corneal complications."	7.67	Serious corneal complications of glaucoma filtering surgery with postoperative 5-fluorouracil. ( Driebe, WT; Heuer, DK; Knapp, A; Stern, GA, 1987)
"Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)."	6.71	Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003)
"Late postoperative complications are similar with the exception of an increased incidence of Tenon cyst formation in the MMC-treated eyes."	6.68	Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. ( Bergstrom, TJ; Higginbotham, EJ; Johnson, AT; Katz, GJ; Lichter, PR; Musch, DC; Skuta, GL, 1995)
"Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used."	5.69	The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023)
"Metastatic skin lesions of gastric cancers usually appear as nonspecific, firm, and hyperpigmented nodules."	5.51	Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug. ( Covarelli, P; De Giorgi, V; Gori, A; Maida, P; Scarfì, F; Silvestri, F; Trane, L, 2019)
"Thapsigargin was ineffective in this animal model."	5.35	Irrigation with thapsigargin and various concentrations of 5-fluorouracil in a sealed-capsule irrigation device in young rabbit eyes to prevent after-cataract. ( Abdelwahab, MT; Kugelberg, M; Zetterström, C, 2008)
"After-cataract was evaluated in 3 ways: clinically, from photographs, and histologically."	5.33	After-cataract evaluation after using balanced salt solution, distilled deionized water, and 5-fluorouracil with a sealed-capsule irrigation device in the eyes of 4-week-old rabbits. ( Abdelwahab, MT; Kugelberg, M; Kugelberg, U; Zetterström, C, 2006)
" In this study, 5-Fluorouracil (5-FU), a halogenated pyrimidine analogue and a potent anti-mitotic agent, was applied for seven days after trabeculectomy in eighteen complicated and unsuccessful filtering glaucomas, at a daily dosage of 5 mg in the form of 0."	5.29	The role of 5-fluorouracil in complicated glaucomas. ( Das, S; Jilani, FA; Khan, AM, 1993)
"The objective of this article was to study longitudinal changes in bleb morphology (presence of microcysts and bleb height and vascularity) in subjects enrolled in the Singapore 5-Fluorouracil (5-FU) trabeculectomy study."	5.27	Longitudinal Changes in Bleb Height, Vascularity, and Conjunctival Microcysts After Trabeculectomy. ( Aung, T; Htoon, HM; Husain, R; Kumaran, A, 2018)
"To compare the efficacy of transconjunctival needling revision with 5-fluorouracil versus medical treatment in glaucomatous eyes with uncontrolled intraocular pressure due to encapsulated bleb after trabeculectomy."	5.17	Early transconjunctival needling revision with 5-fluorouracil versus medical treatment in encapsulated blebs: a 12-month prospective study. ( Susanna, R; Suzuki, R, 2013)
"Mean (+/-SD) preoperative and 1-year postoperative intraocular pressures in the 5-fluorouracil group were 26."	5.09	Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy. ( Caprioli, J; Chaudhry, IA; O'Connor, DJ; Pasha, MA; Weitzman, ML, 2000)
" 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin."	5.09	Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001)
"To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum."	5.09	Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001)
"To study the effect of 5-Fluorouracil (5-FU) in glaucoma filtration surgery, 13 eyes of 12 patients with glaucoma were subjected to trabeculectomy with intraoperative one minute exposure of 50 mg/ml 5-FU."	5.08	Results of intraoperative 5-fluorouracil in patients undergoing trabeculectomy--pilot trial. ( Garg, D; Rao, BS; Revathi, B; Shelat, B; Vijaya, L, 1996)
"We examined the safety and efficacy of 5-fluorouracil in eyes with open-angle glaucoma undergoing combined cataract removal and filtration surgery."	5.07	5-Fluorouracil after primary combined filtration surgery. ( Gieser, DK; Goldenfeld, M; Krupin, T; Liebmann, JM; Ritch, R; Rosenberg, LF; Ruderman, JM; Shields, MB; Wong, PC, 1994)
"A combined intraoperative and postoperative adjuvant program of 5 minus Fluorouracil (5 FU) for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968."	5.04	Chemotherapy as an adjuvant to surgery for colorectal cancer. ( Brown, PW; Donaldson, M; Horsley, S; Lawrence, W; Lovett, WL; Regelson, W; Ruffner, BW; Terz, JJ, 1975)
"We investigated whether or not postoperative complications (POCs) themselves have a negative survival impact or indirectly worsen the survival due to insufficient adjuvant chemotherapy in a pooled analysis of two large phase III studies performed in Japan PATIENTS AND METHODS: The study examined the patients who enrolled in 1304, phase III study comparing the efficacy of 6 and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III study to confirm the tolerability of oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients."	4.31	The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Yoshikawa, T, 2023)
"The aim of this study was to improve the direct results of reconstructive surgery in patients operated on for complicated forms of colorectal cancer, by using 5-fluorouracil in the postoperative period."	4.12	The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer. ( Irimbetov, S; Osombaev, M; Zhakipbekov, S, 2022)
"We present a case of a 53-year-old female patient who was treated with 5-Fluorouracil (5-FU) after postsurgical contracture."	4.02	Contracture Treatment With 5-FU. ( Borrelli, M; Desales, A; Raskin, J; Talei, B, 2021)
"To investigate the ocular surface changes occurring in eyes with recurrent pterygium post-operatively treated with 5-fluorouracil intralesional injections."	3.91	Ocular surface changes in recurrent pterygium cases post-operatively treated with 5-fluorouracil subconjunctival injections. ( Boto de Los Bueis, A; García Tirado, A; Rivas Jara, L, 2019)
"Rabbit model studies suggested better morphology blebs with equal intraocular pressure (IOP) efficacy as a standard mitomycin C (MMC) trabeculectomy using a novel slow-release drug delivery antifibrotic system delivering small quantities of MMC and 5-fluorouracil (5-FU)."	3.91	Effect of 2 Novel Sustained-release Drug Release Systems on Bleb Fibrosis: An In Vivo Trabeculectomy Study in a Rabbit Model. ( Ayyala, RS; Blake, D; Fullerton, M; Greenberg, E; John, V; Le, C; Mancera, N; Margo, C; Muddasani, N; Satija, C; Singh, S; Swann, FB; Wall, J; Zhang, Z; Zurakowski, D, 2019)
"To evaluate the long-term outcome of trabeculectomy with intra- and postoperative 5-fluorouracil (5-FU) application in glaucoma."	3.85	Three-Year Follow-Up of Trabeculectomy with 5-Fluorouracil. ( Koutsonas, A; Kuerten, D; Lindemann, F; Plange, N; Schimitzek, H, 2017)
"To examine the effect of mitomycin c and 5-flurouracil on treatment outcomes following Ahmed glaucoma valve implantation."	3.85	Effect of mitomycin c and 5-flurouracil adjuvant therapy on the outcomes of Ahmed glaucoma valve implantation. ( Cui, QN; Han, Y; Hsia, YC; Lin, SC; Mehta, N; Naseri, A; Porco, TC; Rose-Nussbaumer, J; Stamper, RL, 2017)
"This study was designed to investigate whether 5-fluorouracil (5-Fu)-polycaprolactone sustained-release film in Ahmed glaucoma valve implantation inhibits postoperative bleb scarring in rabbit eyes."	3.81	Application of 5-Fluorouracil-Polycaprolactone Sustained-Release Film in Ahmed Glaucoma Valve Implantation Inhibits Postoperative Bleb Scarring in Rabbit Eyes. ( Bi, XZ; Li, CH; Nan, KH; Pan, WH; Ren, ZJ; Song, ZM; Sun, M; Yu, XP, 2015)
"Bevacizumab reduced the spinal epidural fibrosis significantly that developed in rats after laminectomy and 5-Fluorouracil combination had a synergic effect."	3.80	The effect of bevacizumab and 5-Fluorouracil combination on epidural fibrosis in a rat laminectomy model. ( Ercan, S; Firat, U; Kemaloglu, S; Osun, A; Ozkan, U; Samancioglu, A, 2014)
"To determine whether primary trabeculectomies performed in a UK district general hospital, specifically without making use of mitomycin-C augmentation but with selective use of the low potency anti-metabolite 5-fluorouracil, produce an acceptable long-term intraocular pressure (IOP)-lowering effect for an unselected patient group."	3.79	Enhanced trabeculectomy in a UK district general hospital setting: is selective use of 5-fluorouracil all that is required? ( Chaudhry, N; de Klerk, TA; Moriarty, AP, 2013)
"We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)."	3.78	Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. ( Aloia, TA; Andreou, A; Brouquet, A; Chen, SS; Curley, SA; Garrett, C; Kopetz, S; Maru, DM; Overman, MJ; Shindoh, J; Vauthey, JN; Zimmitti, G, 2012)
"To determine whether the use of postoperative subconjunctival 5-fluorouracil (5-FU) reduces the risk of trabeculectomy bleb failure after uncomplicated small incisional cataract surgery."	3.76	Use of 5-Fluorouracil injections to reduce the risk of trabeculectomy bleb failure after cataract surgery. ( Salmon, JF; Shahid, H, 2010)
"Although adjunctive postoperative 5-fluorouracil (5-FU) injections are known to improve the success rate of glaucoma surgery, it is still unknown what dose, timing and frequency of application will give the best results with respect to the inhibition of postoperative scarring and intraocular pressure regulation."	3.74	Dose, timing and frequency of subconjunctival 5-fluorouracil injections after glaucoma filtering surgery. ( Bartz-Schmidt, KU; Besch, D; Denk, PO; Grüb, M; Reinthal, EK, 2007)
"To report the experience with trabeculectomy augmented with mitomycin C and 5-fluorouracil for the treatment of paediatric glaucoma."	3.73	Augmented trabeculectomy in paediatric glaucoma. ( Ehrlich, R; Friling, R; Gaton, DD; Lusky, M; Snir, M; Weinberger, D, 2005)
"To prospectively study the evolution of possible high risk features of conjunctival filtration blebs like avascularity, transconjunctival oozing (TCO), and leaks after mitomycin C (MMC) enhanced glaucoma surgery."	3.73	Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. ( Anand, N; Arora, S; Clowes, M, 2006)
"To observe the effect of the means of subconjunctiva injection with 5-Fluorouracil (5-Fu) and Triamcinolone to treat the membrane on the anterior surface of intraocular lens after traumatic cataract surgery."	3.73	[Combined 5-Fu and triamcinolone to treat the membrane on the anterior surface of intraocular lens after the surgery of traumatic cataract]. ( Chen, L; Xu, D; Ye, K, 2005)
"To investigate the influence of 5-fluorouracil (5-FU) and mitomycin C (MMC) on the postoperative adhesions following strabismus surgery in rabbits."	3.72	Effects of intraoperative sponge mitomycin C and 5-fluorouracil on scar formation following strabismus surgery in rabbits. ( Düzcan, E; Eşme, A; Ozden, S; Tatlipinar, S; Yaylali, V; Yildirim, C, 2004)
"To assess the outcome of trabeculectomy supplemented with intraoperative 5-Fluorouracil (5 FU) application in glaucoma patients."	3.70	Modification of trabeculectomy with single-dose intraoperative 5-Fluorouracil application. ( Anand, N; Menage, MJ; Sahni, K, 1998)
"Bleb leakage occurred in 14 eyes following trabeculectomy (mitomycin C treatment, 10 eyes; 5-fluorouracil treatment, 3 eyes; no antifibrosis agent, 1 eye) and in 1 eye following combined cataract and glaucoma surgery with adjunctive mitomycin C therapy."	3.70	Late-onset bleb leaks after glaucoma filtering surgery. ( Greenfield, DS; Jee, J; Liebmann, JM; Ritch, R, 1998)
"The use of adjunctive antimetabolites such as 5-fluorouracil (5-FU) and mitomycin C (MMC) in trabeculectomy has caused an increased concern as to the risk of bleb-associated endophthalmitis."	3.70	Late-onset, bleb-associated endophthalmitis following glaucoma filtering surgery with or without antifibrotic agents. ( Frucht-Pery, J; Solomon, A; Ticho, U, 1999)
"To study the association between after-cataract and secondary glaucoma after lensectomy and 5-fluorouracil treatment in an experimental infant rabbit model."	3.70	After-cataract and secondary glaucoma in the aphakic infant rabbit. ( Holmén, JB; Kugelberg, U; Lundgren, B; Lundvall, A; Zetterström, C, 2000)
"A concurrent series (from January 1, 1987, to October 1, 1997) of one surgeon's consecutive 585 (456 patients) combined cataract extraction, intraocular lens implantation, and trabeculectomy surgeries, some with intraoperative mitomycin C and/or postoperative subconjunctival 5-fluorouracil."	3.70	Outcomes of combined cataract extraction, lens implantation, and trabeculectomy surgeries. ( Hahn, J; Larive, B; Rockwood, EJ, 2000)
"To evaluate intraocular pressure (IOP) control and surgical complications following trabeculectomy with 5-fluorouracil (5-FU) or mitomycin at the inferior limbus."	3.69	Trabeculectomy at the inferior limbus. ( Caronia, RM; Cohen, H; Friedman, R; Liebmann, JM; Ritch, R, 1996)
"5-Fluorouracil (5-FU) is useful as an adjunct treatment for glaucoma filtering surgery."	3.69	[Biodegradable controlled-release 5-FU implant in the surgery for glaucoma. Experimental study]. ( Hostyn, P; Kühne, F; Malek-Chehire, N; Parel, JM; Parrish RK, II; Takesue, Y; Villain, F, 1996)
"Administration of subconjunctival 5-fluorouracil (5-FU) and topical mitomycin-C (MMC) has been shown to improve the success rate of glaucoma-filtering surgery."	3.69	A novel MMC-loaded pHEMA drainage device for the treatment of glaucoma: in vitro and in vivo studies. ( Akata, RF; Gökçe, M; Kiremitçi-Gümüşderelioglu, M, 1996)
"To determine whether 5-fluorouracil is effective in reducing scarring after strabismus surgery we used rectus muscle surgery in experimental animals to compare a single intraoperative dose of 5-fluorouracil with mitomycin C and to compare results in similarly treated controls not receiving these antimetabolites."	3.69	Intraoperative sponge 5-fluorouracil to reduce postoperative scarring in strabismus surgery. ( Evan, AP; Helveston, EM; Mora, JS; Sprunger, DT, 1997)
"In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed."	3.68	A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993)
"To investigate the incidence of complications reportedly caused by the use of 5-fluorouracil (5-FU) in glaucoma filtering surgery, we performed trabeculectomy with 5-FU on 57 eyes of 56 patients with advanced glaucoma."	3.68	Incidence of complications following 5-fluorouracil with trabeculectomies. ( Gieser, SC; Jacob, A; Raju, R; Sen, S; Thomas, R, 1993)
"Between 2/1991 and 1/1993 twenty-nine eyes of 11 female and 16 male patients with high-risk glaucoma (unsuccessful previous filtering surgery and a high risk of scarring) were treated with subconjunctival injections of 5-Fluorouracil after filtering surgery in the University Eye Hospital Düsseldorf."	3.68	[5-fluorouracil injection treatment after fistulating glaucoma operations]. ( Klüppel, M; Reinhard, T; Sundmacher, R, 1993)
"Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection."	3.68	Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. ( Adkins, RB; Hoff, SJ; Johnson, DH; Merrill, WH; Murray, MJ; Sawyers, JL; Stewart, JR, 1993)
"54 patients (66 eyes) of late primary glaucoma were divided into 5-Fluorouracil and control groups before trabeculectomy surgery."	3.68	[The anti-cicatrization effect of low dosage 5-Fu after trabeculectomy in late glaucoma]. ( Xiong, XL, 1993)
"We studied 105 patients (105 eyes) operated on for glaucoma with adjunctive fluorouracil, who were followed up for 12 to 48 months (mean, 34."	3.68	Late complications after glaucoma filtering surgery with adjunctive 5-fluorouracil. ( Ophir, A; Ticho, U, 1993)
" These observations have lead to the widespread clinical use in humans of 5-fluorouracil and more recently mitomycin-C in glaucoma filtering surgery."	3.68	Antimetabolites in the surgical treatment of glaucomas. ( Van Caelenberghe, E; Van Oye, R, 1992)
"Twenty-one eyes of 18 patients with uncontrolled glaucoma and intraocular inflammatory disease had glaucoma filtering surgery with postoperative subconjunctival 5-fluorouracil (5-FU)."	3.68	Glaucoma filtering surgery with postoperative 5-fluorouracil in patients with intraocular inflammatory disease. ( Lowder, CY; Meisler, DM; Patitsas, CJ; Rockwood, EJ, 1992)
" Twenty-eight patients with cytologic or histologic proof of localized adenocarcinoma of the pancreatic head received preoperative chemoradiation (fluorouracil, 300 mg/m2 per day, and 50."	3.68	Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. ( Ames, FC; Byrd, DR; Charnsangavej, C; Cleary, KR; Connelly, JH; Evans, DB; Fenoglio, CJ; Levin, B; Rich, TA, 1992)
"Six patients, each with one eye that had previously undergone circular buckling surgery for the repair of retinal detachment before or followed by cataract extraction with or without intraocular lens implantation, underwent trabeculectomy with 5-fluorouracil (5-FU) for intractable glaucoma."	3.68	Trabeculectomy with 5-fluorouracil subsequent to circular buckling operation and cataract extraction. ( Ophir, A; Ticho, U, 1992)
"The effectiveness of trabeculectomy with adjunctive low-dose 5-fluorouracil (5-FU) as the initial surgical procedure in uncomplicated glaucoma was evaluated retrospectively in a consecutive series of 52 patients (mean follow-up, 18."	3.68	Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. ( Liebmann, JM; Marmor, M; Nunez, J; Ritch, R; Wolner, B, 1991)
"Nine patients (nine eyes) with iridocorneal endothelial (ICE) syndrome underwent trabeculectomy and received postoperative subconjunctival injections of 5-fluorouracil (5-FU) to enhance bleb formation (total 5-FU dose, 30-105 mg; mean, 53."	3.68	5-Fluorouracil after trabeculectomy and the iridocorneal endothelial syndrome. ( Cristol, SM; Grajewski, AL; Parrish, RK; Wright, MM, 1991)
"We reviewed the records of 12 eyes of ten adult patients with inflammatory glaucoma who underwent trabeculectomy with the adjuvant use of 5-fluorouracil between January 1986 and January 1989."	3.68	Trabeculectomy with 5-fluorouracil for adult inflammatory glaucoma. ( Jabs, DA; Jampel, HD; Quigley, HA, 1990)
"5-Fluorouracil (5-FU) was injected subconjunctivally after glaucoma filtering surgery in a pilot study of eyes with poor surgical prognoses."	3.67	5-fluorouracil and glaucoma filtering surgery. II. A pilot study. ( Anderson, DR; Gressel, MG; Heuer, DK; Hodapp, E; Palmberg, PF; Parrish, RK, 1984)
"The antimetabolite 5-fluorouracil (5-FU) was used as adjunctive treatment in glaucomatous eyes with poor prognoses undergoing filtering surgery."	3.67	Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. ( Weinreb, RN, 1987)
"We show that a 40-mg total dose of subconjunctival 5-fluorouracil after glaucoma filtering surgery can provide a success rate comparable to that demonstrated in prior studies employing a higher dose."	3.67	Low-dose 5-fluorouracil and glaucoma filtration surgery. ( Rabowsky, JH; Ruderman, JM, 1989)
"The effect of 5-fluorouracil (5-FU) subconjunctival injection on the bleb formation and intraocular pressure (IOP) following trabeculectomy was studied in 18 glaucoma patients (20 eyes) with poor surgical prognosis."	3.67	5-Fluorouracil for trabeculectomy in glaucoma. ( Kitazawa, Y; Nakano, Y; Shirato, S; Taniguchi, T; Yamamoto, T, 1987)
"We studied four patients who, having received postoperative 5-fluorouracil after glaucoma filtering operations, developed serious corneal complications."	3.67	Serious corneal complications of glaucoma filtering surgery with postoperative 5-fluorouracil. ( Driebe, WT; Heuer, DK; Knapp, A; Stern, GA, 1987)
"Tumor resectability of pancreatic cancer staged as unresectable at primary diagnosis should be reassessed after neoadjuvant treatment."	3.01	R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial. ( Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA, 2021)
"We conducted a prospective study in esophageal cancer patients who received nCT (n = 126) or nCRT (n = 141) prior to surgery."	2.84	Impact of neoadjuvant chemotherapy and chemoradiotherapy on postoperative cardiopulmonary complications in patients with esophageal cancer. ( Zhang, H; Zhang, Z, 2017)
"From January 2011 to January 2016, 696 colorectal cancer patients were enrolled in this study: 341 patients were randomly assigned to the intraoperative chemotherapy, which consist of portal vein chemotherapy, intraluminal chemotherapy and intraperitoneal chemotherapy, plus surgery group, whereas 344 patients were randomized to the control group to undergo surgery alone."	2.84	Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC). ( Chen, G; Ding, PR; Fan, WH; Huang, JQ; Jiang, W; Ke, CF; Kong, LH; Lei, J; Li, C; Li, LR; Lin, JZ; Liu, Q; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zhang, RX; Zhou, WH, 2017)
"To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy."	2.84	Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). ( Ackland, S; Ansari, N; Burmeister, B; Fisher, RJ; Heriot, A; Joseph, D; Mackay, J; McClure, B; McLachlan, SA; Ngan, SY; Solomon, MJ, 2017)
"Consecutive patients with distal rectal cancer undergoing neoadjuvant chemoradiation (50."	2.82	Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. ( Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Jorge, JM; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2016)
" Although the success of trabeculectomy in lowering IOP is reduced when combined with phacoemulsification compared with trabeculectomy alone, this finding has to be set against the possible need for subsequent cataract surgery following trabeculectomy alone, which represents a second trip and expense for the patient and results in 10-61% failure of the trabeculectomy at one year post-cataract surgery."	2.82	Is Beta Radiation Better than 5 Flurouracil as an Adjunct for Trabeculectomy Surgery When Combined with Cataract Surgery? A Randomised Controlled Trial. ( Bowman, R; Cousens, S; Dhalla, K; Murdoch, I; Wood, M, 2016)
"The data from two phase III trials for oesophageal cancer were used."	2.80	Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. ( Ando, N; Fukuda, H; Hayashi, K; Igaki, H; Kataoka, K; Kato, K; Kitagawa, Y; Mizusawa, J; Nakamura, K; Ozawa, S, 2015)
"Data from 62 patients with rectal cancer (uT3-4; N0/1, M0) of the phase II trial were analyzed."	2.79	Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications. ( Arnold, D; Buller, J; Dellas, K; Dunst, J; Görtz, GJ; Höhler, T; Keck, T; Richter, M; Zühlke, H, 2014)
"Capecitabine was administered on weekdays concurrently with pelvic radiotherapy at a daily dose of 1."	2.79	Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. ( Hirakawa, K; Hosono, M; Maeda, K; Miki, Y; Nagahara, H; Shimatani, Y; Tsutsumi, S, 2014)
"This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC)."	2.78	Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. ( Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J, 2013)
"Patients with clinical T3, T4, or N1-2 rectal cancer were subjected to a preoperative CCRT protocol with FOLFOX and bevacizumab (5 mg/kg) biweekly for 6 cycles followed by a standardized laparoscopic TME procedure, as detailed in the attached video."	2.76	Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. ( Cheng, KW; Lai, HS; Liang, JT, 2011)
"Peritoneal carcinomatosis (PC), which has hitherto been regarded as a lethal entity, can now be cured with surgery (treating macroscopic tumor seeding) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) (treating residual microscopic disease)."	2.73	Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. ( Billard, V; Blot, F; Elias, D; Goere, D; Kohneh-Shahri, N; Pocard, M; Raynard, B, 2007)
"Multimodality therapy for esophageal cancer holds promise for improving outcome in this lethal disease."	2.72	Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. ( Beard, M; Cheng, JD; Freedman, G; Goldberg, M; Henry, LR; Konski, A; McLaughlin, S; Meropol, NJ; Scott, W; Watts, P; Weiner, LM, 2006)
"4), use of antiglaucoma medication, dosage of topical steroid postoperatively, and being operated on by a trainee surgeon (odds ratio, 2."	2.72	Effect of trabeculectomy on lens opacities in an East Asian population. ( Aung, T; Chew, PT; Devereux, JG; Foster, PJ; Gazzard, G; Husain, R; Khaw, PT; Oen, FT; Seah, SK, 2006)
"4 Gy/28 fractions) combined with 5-FU (200-225 mg/m(2)/day by continuous venous infusion) and weekly OXA (25-60 mg/m(2))."	2.72	5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. ( Aschele, C; Bruttocao, A; DeSalvo, GL; Fabris, G; Ferraro, B; Finco, C; Frego, M; Friso, ML; Lise, M; Lonardi, S; Nitti, D; Pucciarelli, S; Rugge, M; Toppan, P; Urso, E, 2006)
"In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival."	2.72	Chemotherapy with preoperative radiotherapy in rectal cancer. ( Bardet, E; Beny, A; Bosset, JF; Calais, G; Collette, L; Daban, A; Maingon, P; Mineur, L; Ollier, JC; Radosevic-Jelic, L, 2006)
"Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)."	2.71	Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003)
"Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre or postoperative RCT: A total dose of 50."	2.71	Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. ( Becker, H; Fietkau, R; Hess, C; Hohenberger, W; Karstens, JH; Martus, P; Raab, R; Rödel, C; Sabitzer, H; Sauer, R; Tschmelitsch, J; Wittekind, C, 2003)
"Sixty lower rectal cancer patients were divided randomly into two groups."	2.71	[Combined preoperative xeloda and radiotherapy for lower rectal cancer]. ( Cai, GY; Li, TH; Wu, JW; Zhuang, CP, 2003)
" A study was conducted of a novel treatment, EMR combined with CRT, for patients with superficial esophageal carcinoma."	2.71	EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous-cell carcinoma. ( Asaka, M; Fujita, M; Hosokawa, M; Kato, M; Nakagawa, S; Shimizu, Y; Tsukagoshi, H; Yamamoto, J, 2004)
"Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50."	2.70	Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). ( Becker, H; Fietkau, R; Hess, C; Hohenberger, W; Jatzko, G; Karstens, JH; Martus, P; Raab, R; Rödel, C; Sabitzer, H; Sauer, R; Wittekind, C, 2001)
"Postoperative complications were reported in 146 (41%) CS and 161 (42%) S patients."	2.70	Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. ( , 2002)
"Two hundred forty-eight gastric cancer patients thought to have resectable cancer were randomized intraoperatively to receive EPIC with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5 versus surgery only."	2.69	Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. ( Averbach, A; Chang, D; Sugarbaker, PH; Whang, I; Yu, W, 1998)
"Hypertrophic scars and keloids may complicate wound healing secondary to trauma or surgery."	2.69	Treatment of inflamed hypertrophic scars using intralesional 5-FU. ( Fitzpatrick, RE, 1999)
"When comparing the different types of open angle glaucoma, no difference was found in terms of reduction in IOP, number of patients requiring antiglaucoma medications, or success rate."	2.69	Deep sclerectomy with collagen implant: medium term results. ( Karlen, ME; Mermoud, A; Sanchez, E; Schnyder, CC; Sickenberg, M, 1999)
"5-Fluorouracil and MMC were found to be equally safe and effective adjuncts to primary trabeculectomy in the short- and medium-term postoperative periods."	2.69	Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. ( Baerveldt, GS; Budenz, DL; Chen, PP; Cohen, JS; Greenfield, DS; Mehta, K; Moster, MR; Shaikh, NM; Shaikh, S; Singh, K; Tsai, JC, 2000)
"Six patients (21%) had residual cancer in the resected specimen, either at the primary site or--more often--in adjacent lymph nodes."	2.68	Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995)
"Late postoperative complications are similar with the exception of an increased incidence of Tenon cyst formation in the MMC-treated eyes."	2.68	Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery. Extended follow-up. ( Bergstrom, TJ; Higginbotham, EJ; Johnson, AT; Katz, GJ; Lichter, PR; Musch, DC; Skuta, GL, 1995)
"After a median follow-up of 9 years, disease progression was reported in 40% of patients in the control group, 40% in the HEP group and 29% in the HEP/5-FU group."	2.68	Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Can ( Couvreur, ML; Curran, D; dos Santos, JG; Lise, M; Nitti, D; Rauschecker, H; Roelofsen, F; Sahmoud, T; Stremmel, W; Wils, J, 1997)
"The risk of suprachoroidal hemorrhage was strongly associated with the level of the preoperative intraocular pressure."	2.67	Risk factors for suprachoroidal hemorrhage after filtering surgery. The Fluorouracil Filtering Surgery Study Group. ( , 1992)
"After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy."	2.67	[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990)
"BACKGROUND Gastric cancer metastasis to the appendix is a rare condition that might present with symptoms of acute appendicitis or remain asymptomatic and be diagnosed incidentally."	2.66	Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review. ( Aburahmah, M; Alhadid, D; Almana, H; AlShammari, A, 2020)
" The LT 5-FU was given at a dosage of 750 mg/m2 every 2 weeks for 18 months or until progression."	2.66	Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. ( Bleiberg, H; Buyse, M; Dalesio, O; Gerard, A; Gignoux, M; Goffin, JC; Michel, J; Pector, JC; Roussel, A; Samana, G, 1989)
" Furthermore, the survival was elevated in proportion to the increase of total dosage of futraful."	2.65	[Effect of postoperative long-term chemotherapy of stomach cancer using mitomycin C and futraful--the secondary study (1)]. ( Abe, O; Akiyama, H; Hattori, T; Hayasaka, A; Inokuchi, K; Inoue, K; Ito, I; Kasai, Y; Kikuchi, K; Kondo, T; Muto, T; Nakajima, T; Sugie, S; Taguchi, T, 1982)
"The treatment of rectal cancer has evolved significantly in recent decades."	2.49	[Radiotherapy-associated morbidity and mortality in rectal surgery]. ( Büchler, MW; Kulu, Y; Ulrich, A, 2013)
"For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear."	2.48	Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012)
" The optimum route of administration and dosing regimen of anti-VEGF antibodies and their positioning in comparison with 5-fluorouracil and mitomycin C are uncertain."	2.47	Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery. ( Barton, K; Mathew, R, 2011)
"Treatment of rectal cancer over the last two decades has evolved with changes in techniques of surgery and radiation based on national and international trials."	2.44	Total mesorectal excision and management of rectal cancer. ( Phang, PT; Pinsk, I, 2007)
"In patients with resectable pancreatic cancer, particularly in UICC-stage II neoadjuvant radiochemotherapy, this results in an improvement in survival: the median survival is between 15 and 30 months."	2.42	[Pancreatic cancer. The relative importance of neoadjuvant therapy]. ( Beger, HG; Gansauge, F; Poch, B; Schwarz, M, 2003)
"Filtering bleb encapsulation may, in some cases, be a severe complication following filtering surgery."	2.38	Encapsulated filtering bleb. A selective review--new deductions. ( Ophir, A, 1992)
"The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated."	1.91	Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers. ( Doki, Y; Kakeji, Y; Kawakubo, H; Kitagawa, Y; Matsuda, S; Muto, M; Okamura, A; Okui, J; Takemura, R; Takeuchi, H; Watanabe, M, 2023)
"Capecitabine (CAP) is a classic antimetabolic drug and has shown potential antirejection effects after liver transplantation (LT) in clinical studies."	1.91	Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients' T cell ferroptosis. ( Cao, L; Fan, SL; Kong, DJ; Li, JH; Liu, T; Ren, JS; Shen, ZY; Song, ZL; Wang, H; Wang, JX; Wang, ZL; Yang, RN; Yoshida, S; Zhang, S; Zheng, H, 2023)
"Combining colorectal resection with HAI pump implantation is a safe surgical approach for management of unresectable CRLM."	1.72	Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases. ( Allen, PJ; Creasy, JM; Lan, B; Lidsky, ME; Mantyh, CR; Migaly, J; Moore, C; Sharib, J; Thacker, JKM; Turley, MC; Zani, S, 2022)
"Three patients (25%) developed anastomotic leakage."	1.56	Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. ( Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S, 2020)
"Esophageal cancer is increasingly common and carries a poor prognosis."	1.56	Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020)
"Metastatic skin lesions of gastric cancers usually appear as nonspecific, firm, and hyperpigmented nodules."	1.51	Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug. ( Covarelli, P; De Giorgi, V; Gori, A; Maida, P; Scarfì, F; Silvestri, F; Trane, L, 2019)
" There was no significant adverse event for either group and no significant IOP difference in any of the observational periods between them (P=0."	1.51	Comparison of Efficacy and Safety of Bleb Needle Revision With and Without 5-Fluorouracil for Failing Trabeculectomy Bleb. ( Jeoung, JW; Kim, HJ; Kim, JS; Kim, YK; Na, KI; Park, KH, 2019)
"Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy."	1.51	Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis. ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019)
"Approximately 30% of all pancreatic cancer patients have locally advanced (AJCC stage 3) disease."	1.48	Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. ( Besselink, MG; Boggi, U; Hackert, T; Klompmaker, S; Salvia, R; Weiss, M; Yamaue, H; Zeh, HJ, 2018)
"Esophageal cancer is the eighth most common cancer worldwide."	1.46	Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience. ( Chen, Y; Hao, D; He, C; Liu, J; Wang, J; Wang, W; Wu, X; Xing, W; Yang, Y, 2017)
"Rectal cancer is a malignant disease requiring multidisciplinary management."	1.46	Management of rectal cancer: the 2016 French guidelines. ( Bridoux, V; Brouquet, A; de Chaisemartin, C; Kirzin, S; Lakkis, Z; Lefevre, JH; Maggiori, L; Manceau, G; Panis, Y, 2017)
"Patients with pathological stage II/III gastric cancer undergoing LG with D2 lymphadenectomy (LG group: n = 74) were matched 1:1 with patients selected from 214 similar patients undergoing OG (OG group: n = 74), identically matching gender, age, pathological stage, and type of gastrectomy, and comparing AC initiation timing between the two groups."	1.46	Timing of initiation of adjuvant chemotherapy for gastric cancer: A case-matched comparison study of laparoscopic vs. open surgery. ( Kaito, A; Kinoshita, T; Nishida, T; Shibasaki, H; Shitara, K, 2017)
"The aim of this study was to assess the risk of HCs after CRS combined with HIPEC-Ox versus other drugs, and to determine predictive factors for HCs after HIPEC-Ox."	1.43	Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. ( Charrier, T; Cotte, E; Elias, D; Eveno, C; Glehen, O; Gocevska, S; Goere, D; Maurice, C; Ortega-Deballon, P; Passot, G; Peron, J; Pocard, M; Quénet, F; Vaudoyer, D, 2016)
"Patients with resectable oesophageal cancer are treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery within 3-8 weeks."	1.43	Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. ( Creemers, GJ; Kathiravetpillai, N; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ, 2016)
" This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value."	1.43	Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016)
"436 patients with unresectable pancreatic cancers received HIFU treatment; the other 253 patients received non-HIFU treatment."	1.43	A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. ( Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP, 2016)
"Following recurrence of cancer of the sigmoid colon, the patient received a course of XELOX plus bevacizumab(Bmab)to treat peritoneal dissemination and lung metastases."	1.43	[A Case of Aortoesophageal Fistula Rupture Due to Descending Thoracic Aortic Dissection with Recurrent Colon Cancer during Chemotherapy Containing Bevacizumab]. ( Fujii, T; Funahashi, K; Kaneko, H; Kaneko, T; Katayanagi, T; Koda, T; Koike, J; Kurihara, A; Masuhara, H; Sawaguchi, Y; Shimada, H; Shiokawa, H; Suzuki, T; Ushigome, M; Watanabe, Y, 2016)
"NACRT before major rectal cancer surgery significantly decreased physical fitness as assessed by CPET."	1.40	The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients. ( Barben, CP; Grocott, MP; Jack, S; Kemp, GJ; Loughney, L; Sripadam, R; West, MA, 2014)
"Postoperative complications were graded according to the Clavien-Dindo classification."	1.40	Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. ( Baba, H; Baba, Y; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N, 2014)
"Postoperative complications were graded according to the Clavien-Dindo classification."	1.40	Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer. ( Berkel, AE; Klaase, JM; van der Palen, J; Woutersen, DP, 2014)
"Postoperative complications have had occurred in 12."	1.39	[Immediate results of complex treatment of resectable rectal neoplasms of distal localization]. ( Basheev, VKh; Bondar', GV; Sovpel', IV; Sovpel', OV; Zolotukhin, SÉ, 2013)
"Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection."	1.39	Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. ( Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F, 2013)
"Major postoperative complications were independently associated with major (≥ 3 segments) resections (57%) and perioperative blood transfusion."	1.39	Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. ( Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS, 2013)
" CRT combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) was administered to all patients."	1.39	Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer. ( Hayashi, R; Ikematsu, H; Ito, M; Kaneko, K; Kojima, T; Minashi, K; Ohtsu, A; Onozawa, M; Oono, Y; Satake, H; Yajima, Y; Yano, T; Yoda, Y, 2013)
"Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery."	1.39	Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013)
"Major forms of oral candidiasis are pseudomembranous and atrophic form, but chronic hyperplastic candidiasis (CHC) is rarely seen."	1.37	Oral candidiasis mimicking tongue cancer. ( Hasegawa, S; Hashikawa, K; Nibu, K; Otsuki, N; Saito, M; Shibata, T; Tahara, S; Yamashita, D, 2011)
"Capecitabine is an attractive radiosensitizer."	1.37	Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. ( Cats, A; Gerhards, MF; Heuff, G; Marijnen, CA; Swellengrebel, HA; van Geloven, AA; van Tets, WF; Verheij, M; Verwaal, VJ; Vincent, A, 2011)
"Postoperative recurrence or distant metastasis was observed in 7/10 of FP patients and 5/12 of DCF patients."	1.37	Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. ( Abe, T; Hatooka, S; Kondo, C; Mizota, A; Muro, K; Nomura, M; Shinoda, M; Shitara, K; Takahari, D; Ura, T; Yatabe, Y; Yokota, T, 2011)
"Local postoperative complications affected 25 of 61 patients, who had lower perioperative neutrophil increases than their counterparts (P = 0."	1.36	Suppression of the postoperative neutrophil leucocytosis following neoadjuvant chemoradiotherapy for rectal cancer and implications for surgical morbidity. ( Glynne-Jones, R; Kerr, SF; Klonizakis, M, 2010)
"Rectal tumors were localized within 12 cm from the anocutaneous verge."	1.36	Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment. ( Bartos, J; Czudek, S; Gruna, J; Kycina, R; Parvez, J; Skrovina, M; Soumarova, R; Wendrinski, A, 2010)
"Squamous cell carcinoma was an adverse factor related to increased postoperative pulmonary complications."	1.36	High-dose preoperative chemoradiotherapy in esophageal cancer patients does not increase postoperative pulmonary complications: correlation with dose-volume histogram parameters. ( Hurmuzlu, M; Muren, LP; Smaaland, R; Viste, A; Wentzel-Larsen, T; Øvrebø, K, 2010)
"Twenty men with primary rectal cancer clinically involving the lower urinary tract organs underwent extended colorectal resection combined with radical prostatectomy."	1.36	Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract. ( Ito, M; Kobayashi, A; Minagawa, N; Nishizawa, Y; Saito, N; Sugito, M; Suzuki, T; Tanaka, T; Watanabe, K, 2010)
" Based on the Wuerzburg bleb classification score (WBCS) for postoperative wound healing evaluation, 30 of these operations of group A (group B: n = 26) did not receive 5 FU postoperatively (controls), 67 (93) received up to 7 postoperative injections of 5 mg 5 FU (normal dosage group), and 72 (93) received more than 7 injections (high dosage group)."	1.36	[Corneal epitheliopathy following trabeculectomy with postoperative adjunctive 5-fluorouracil]. ( Geerling, G; Grehn, F; Klink, T; Reiter, C; Schultheiss, A; Wimmer, S, 2010)
"Local therapy for early rectal cancer is a valid alternative to the classical radical operation, which has a higher morbidity and mortality rate."	1.35	Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience. ( Baldarelli, M; Bartolacci, S; Grillo Ruggeri, F; Guerrieri, M; Lezoche, E; Mantello, G; Organetti, L, 2008)
"Two fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis are reported here."	1.35	Fatal pneumonitis induced by oxaliplatin. ( Arévalo Lobera, S; Azkue Gabilondo, M; Basterretxea Badiola, L; Egaña Otaño, L; Elejoste Echeberría, I; La Casta Muñoa, A; Melé Olivé, M; Sagastibeltza Mariñelarena, N, 2008)
"Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18."	1.35	[Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009)
"Thapsigargin was ineffective in this animal model."	1.35	Irrigation with thapsigargin and various concentrations of 5-fluorouracil in a sealed-capsule irrigation device in young rabbit eyes to prevent after-cataract. ( Abdelwahab, MT; Kugelberg, M; Zetterström, C, 2008)
"About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases."	1.34	Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? ( Amisano, M; Bouzari, H; Capussotti, L; Massucco, P; Muratore, A; Sperti, E; Zorzi, D, 2007)
"Irrigation with 5-FU 50 mg/mL in the sealed-capsule irrigation device was safe and caused no apparent damage to the adjacent intraocular tissues."	1.34	Safety of irrigation with 5-fluorouracil in a sealed-capsule irrigation device in the rabbit eye. ( Abdelwahab, MT; Kugelberg, M; Seregard, S; Zetterström, C, 2007)
"Twenty-six patients with non-metastatic rectal cancer >T1 on pathologic TNM staging who underwent primary laparoscopic surgery were considered for comparison."	1.34	Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy. ( Bona, S; Elmore, U; Furlan, N; Romario, UF; Rosati, R, 2007)
"The adjuvant treatment of rectal cancer is a rapidly evolving field."	1.33	Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer. ( Chao, M; Cullinan, M; Faragher, I; Gibbs, P; Jones, I; McLaughlin, S; Skinner, I; Tjandra, J, 2005)
"Data from 110 esophageal cancer patients treated between January 1998 and December 2003 were analyzed retrospectively."	1.33	Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. ( Ajani, JA; Cox, JD; Komaki, R; Liao, Z; Liu, H; Swisher, S; Tucker, SL; Vaporciyan, AA; Wang, SL; Wei, X, 2006)
"After-cataract was evaluated in 3 ways: clinically, from photographs, and histologically."	1.33	After-cataract evaluation after using balanced salt solution, distilled deionized water, and 5-fluorouracil with a sealed-capsule irrigation device in the eyes of 4-week-old rabbits. ( Abdelwahab, MT; Kugelberg, M; Kugelberg, U; Zetterström, C, 2006)
"Curative surgery for rectal cancer seldom requires urinary tract resections."	1.32	Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival. ( Chwaliński, M; Nowacki, MP; Oledzki, J; Rogowski, W; Sopyło, R, 2004)
"One hundred and fifty-five rectal cancer patients undergoing preoperative pelvic external beam radiation therapy and 5-fluorouracil-based chemotherapy followed by rectal resection were identified."	1.32	Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. ( Gittleman, AE; Guillem, JG; Minsky, BD; Moore, HG; Paty, PB; Saltz, L; Shia, J; Temple, L; Weiser, M; Wong, D, 2004)
"Rare reports of intestinal obstruction have been confined to the stiff plastic and stainless-steel stents."	1.32	A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). ( Ho, HS; Ong, HS, 2004)
"Postoperative complications were anastomosis leakage in 1 patient, and anastomosis stenosis in 2 and esophagobronchial fistula in 1."	1.31	[Salvage operation for esophageal cancer after radical chemoradiotherapy]. ( Boku, N; Gotohda, N; Nagai, K; Nishimura, M; Ohtsu, A; Yoshida, J, 2002)
"Eight patients had synchronous distant metastases."	1.31	Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer. ( Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Rödel, C; Sauer, R; Schick, C, 2000)
"If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD."	1.31	Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002)
"Intraocular pressure was significantly lower and an avascular area was more frequent in eyes with oozing or leak than in eyes without (P <."	1.31	Late-onset transconjunctival oozing and point leak of aqueous humor from filtering bleb after trabeculectomy. ( Araie, M; Matsuo, H; Shirato, S; Suzuki, Y; Tomidokoro, A, 2002)
"Mitomycin C was administered intraoperatively in the dose of 0."	1.31	[Antimetabolites in glaucoma surgery--long-term results]. ( Ferková, S; Jakabovicová, E; Michalíková, L; Strmen, P, 2002)
"Suspected pulmonary embolism was demonstrated by CT scan."	1.31	[Complicated antiphospholid antibody syndrome]. ( Eifrig, B; Hegewisch-Becker, S; Hossfeld, DK; Langer, F; Marx, G; Neuber, K, 2002)
" Depending on the location of the anastomosis and the route of 5-FU administration, even a period of 3 days between operation and first dosage seemed insufficient to prevent weakening of the anastomosis."	1.30	Is early post-operative treatment with 5-fluorouracil possible without affecting anastomotic strength in the intestine? ( de Man, BM; Hendriks, T; van der Kolk, BM; Wobbes, T, 1999)
" Preoperative chemoradiotherapy consisted of cisplatinum combined chemotherapy and radiotherapy (total dosage of 30-70 Gy)."	1.30	Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy. ( Eguchi, R; Hayashi, K; Ide, H; Itoh, H; Nakamura, T; Ohta, M; Okamoto, F; Takasaki, K, 1999)
"In patients with locally advanced cervical cancer, most of the treatment failures occur within the pelvis."	1.29	Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. ( Boubli, L; Cowen, D; Delpero, JR; Gamerre, M; Gouvernet, J; Houvenaeghel, G; Noirclerc, M; Perez, T; Resbeut, M; Viens, P, 1994)
" In this study, 5-Fluorouracil (5-FU), a halogenated pyrimidine analogue and a potent anti-mitotic agent, was applied for seven days after trabeculectomy in eighteen complicated and unsuccessful filtering glaucomas, at a daily dosage of 5 mg in the form of 0."	1.29	The role of 5-fluorouracil in complicated glaucomas. ( Das, S; Jilani, FA; Khan, AM, 1993)
"5-Fluorouracil (5-FU) has been used to improve the outcome of trabeculectomy in high-risk cases, employing a postoperative regimen of subconjunctival injections."	1.29	Low-dose perioperative 5-fluorouracil in trabeculectomy. ( Hugkulstone, CE; Vernon, SA, 1996)
"In 56 patients with a 3d stage gastric cancer regional intraarterial chemotherapy with 5-fluorouracil was used pre- and postoperatively."	1.29	[The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy]. ( Makarkin, NA; Tikhonov, VI; Tuzikov, SA; Zyrianov, BN, 1996)
" In addition, toxic effects of 5-FU on existing fibroblasts, in rabbits and in vitro, were demonstrated."	1.28	Toxic effects of 5-fluorouracil on fibroblasts following trabeculectomy. ( Ophir, A; Ticho, U, 1992)
"Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy."	1.28	Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989)
"Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment."	1.27	Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983)
"Pseudomyxoma peritonei is an unusual malignancy arising from the goblet cells of the large bowel or appendix."	1.27	Malignant pseudomyxoma peritonei of colonic origin. Natural history and presentation of a curative approach to treatment. ( Kern, K; Lack, E; Sugarbaker, PH, 1987)
"40 patients with primary or metastatic liver malignancies have been treated with hepatic dearterialization, 19 of them in combination with regional infusion with 5-fluoroacil."	1.26	Results of liver dearterialization combined with regional infusion of 5-fluorouracil for liver cancer. ( Almersjö, O; Bengmark, S; Hafström, L; Leissner, KH, 1976)

Research

Studies (487)

Authors

Clinical Trials (55)

Trial Overview

Trial Outcomes

Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.

Timeframe	Studies, this research(%)	All Research%
pre-1990	65 (13.35)	18.7374
1990's	126 (25.87)	18.2507
2000's	137 (28.13)	29.6817
2010's	131 (26.90)	24.3611
2020's	28 (5.75)	2.80

Authors	Studies
Suzuki, H	1
Niizeki, T	1
Shirono, T	1
Koteda, Y	1
Kinjyo, Y	1
Mizukami, N	1
Koda, M	1
Ota, S	1
Nakano, M	1
Okamura, S	1
Iwamoto, H	1
Shimose, S	1
Noda, Y	1
Kamachi, N	1
Kajiwara, A	1
Suda, K	1
Akiba, J	2
Yano, H	2
Kuromatsu, R	1
Koga, H	1
Torimura, T	1
Turley, MC	1
Moore, C	1
Creasy, JM	1
Sharib, J	1
Lan, B	1
Thacker, JKM	1
Migaly, J	1
Zani, S	1
Allen, PJ	2
Mantyh, CR	1
Lidsky, ME	1
Peng, SH	1
Mbarak, HS	1
Li, YH	2
Ma, C	1
Shang, QL	1
Chen, Z	2
Bian, DJ	1
Xiao, EH	1
Zhakipbekov, S	1
Osombaev, M	1
Irimbetov, S	1
Aoyama, S	2
Motoori, M	4
Yamasaki, M	6
Shiraishi, O	4
Miyata, H	6
Hirao, M	4
Takeno, A	3
Sugimura, K	3
Makino, T	4
Tanaka, K	3
Hamakawa, T	2
Yamashita, K	2
Kimura, Y	4
Fujitani, K	4
Yasuda, T	4
Yano, M	4
Doki, Y	7
Matsuda, S	1
Kitagawa, Y	2
Okui, J	1
Okamura, A	1
Kawakubo, H	1
Takemura, R	1
Muto, M	2
Kakeji, Y	1
Takeuchi, H	1
Watanabe, M	2
Aoyama, T	1
Oba, K	1
Honda, M	1
Mayanagi, S	1
Maeda, H	1
Kanda, M	1
Kashiwabara, K	1
Sakamoto, J	1
Yoshikawa, T	1
Wang, H	1
Wang, ZL	1
Zhang, S	1
Kong, DJ	1
Yang, RN	1
Cao, L	1
Wang, JX	1
Yoshida, S	2
Song, ZL	1
Liu, T	1
Fan, SL	1
Ren, JS	1
Li, JH	1
Shen, ZY	1
Zheng, H	1
Okumura, S	1
Goumard, C	1
Gayet, B	1
Fuks, D	1
Scatton, O	1
Shindoh, J	2
Kobayashi, Y	1
Kinowaki, K	1
Mise, Y	1
Gonoi, W	1
Tani, K	1
Matoba, S	1
Kuroyanagi, H	1
Hashimoto, M	2
De Giorgi, V	1
Scarfì, F	1
Trane, L	1
Silvestri, F	1
Maida, P	1
Gori, A	1
Covarelli, P	1
Treder, M	1
Janssen, S	1
Schild, SE	1
Rades, D	1
Lof, S	1
Korrel, M	1
van Hilst, J	1
Alseidi, A	1
Balzano, G	1
Boggi, U	2
Butturini, G	1
Casadei, R	1
Dokmak, S	1
Edwin, B	1
Falconi, M	1
Keck, T	2
Malleo, G	1
de Pastena, M	1
Tomazic, A	1
Wilmink, H	1
Zerbi, A	1
Besselink, MG	2
Abu Hilal, M	1
Shirakawa, Y	1
Maeda, N	1
Tanabe, S	1
Noma, K	1
Sakurama, K	1
Katsui, K	1
Nishizaki, M	1
Fujiwara, T	1
Alhadid, D	1
AlShammari, A	1
Almana, H	1
Aburahmah, M	1
Le, VNH	1
Wabnig, F	1
Bachmann, B	1
Cursiefen, C	2
Halili, A	1
Kessel, L	1
Subhi, Y	1
Bach-Holm, D	1
Chun, YJ	1
Kim, SG	1
Lee, KW	1
Cho, SH	1
Kim, TW	2
Baek, JY	1
Park, YS	1
Hong, S	1
Chu, CW	1
Beom, SH	1
Jung, M	1
Shin, SJ	1
Ahn, JB	1
Brouquet, A	4
Bachet, JB	1
Huguet, F	1
Karoui, M	1
Artru, P	1
Sabbagh, C	1
Lefèvre, JH	2
Vernerey, D	1
Mariette, C	3
Vicaut, E	1
Benoist, S	1
Pucher, PH	1
Rahman, SA	1
Walker, RC	1
Grace, BL	1
Bateman, A	1
Iveson, T	1
Jackson, A	1
Rees, C	1
Byrne, JP	1
Kelly, JJ	1
Noble, F	1
Underwood, TJ	1
Weniger, M	1
Moir, J	1
Damm, M	1
Maggino, L	1
Kordes, M	1
Rosendahl, J	1
Ceyhan, GO	1
Schorn, S	1
Fietkau, R	4
Grützmann, R	1
Wittel, UA	1
Croner, RS	1
Jacobasch, L	1
Neumann, UP	1
Reinacher-Schick, A	1
Imhoff, D	1
Boeck, S	1
Keilholz, L	1
Oettle, H	1
Hohenberger, WM	1
Golcher, H	1
Bechstein, WO	1
Uhl, W	1
Pirkl, A	1
Adler, W	1
Semrau, S	1
Rutzner, S	1
Ghadimi, M	1
Lubgan, D	1
Tanishima, Y	1
Nishikawa, K	1
Arakawa, Y	1
Matsumoto, A	1
Yuda, M	1
Tanaka, Y	1
Mitsumori, N	1
Yanaga, K	1
Chen, X	1
Hong, Y	1
Zhang, C	1
Mori, M	3
Eguchi, H	1
Sah, BK	1
Zhang, B	1
Zhang, H	2
Li, J	1
Yuan, F	1
Ma, T	1
Shi, M	1
Xu, W	1
Zhu, Z	2
Liu, W	1
Yan, C	1
Li, C	2
Liu, B	1
Yan, M	1
Kawashima, R	1
Matsushita, K	1
Kawasaki, R	1
Nishida, K	1
Li, K	1
He, X	1
Tong, S	1
Zheng, Y	1
Kim, YJ	1
Cho, E	1
Park, CH	1
Sędłak, K	1
Rawicz-Pruszyński, K	1
Mlak, R	1
Gęca, K	1
Skórzewska, M	1
Pelc, Z	1
Małecka-Massalska, T	1
Polkowski, WP	1
Talei, B	1
Raskin, J	1
Borrelli, M	1
Desales, A	1
Zhang, Z	2
Lindemann, F	1
Plange, N	1
Kuerten, D	1
Schimitzek, H	1
Koutsonas, A	1
Shihadeh, W	1
Massad, I	1
Khader, Y	1
Al-Rawi, A	1
Alshalakhti, T	1
Chen, Y	1
Hao, D	1
Wu, X	1
Xing, W	1
Yang, Y	1
He, C	1
Wang, W	1
Liu, J	1
Wang, J	1
Fatemi, MJ	1
Shirani, S	1
Sobhani, R	1
Lebaschi, AH	1
Gharegozlou, MJ	1
Bagheri, T	1
Pedram, M	1
Saberi, M	1
Araghi, S	1
Fatemi, MA	1
Wirbelauer, C	1
Mertens, CN	1
Kaplowitz, K	1
Tsai, JC	3
Zhang, RX	1
Lin, JZ	1
Lei, J	1
Chen, G	1
Li, LR	1
Lu, ZH	1
Ding, PR	1
Huang, JQ	1
Kong, LH	1
Wang, FL	1
Jiang, W	1
Ke, CF	1
Zhou, WH	1
Fan, WH	1
Liu, Q	1
Wan, DS	1
Wu, XJ	2
Pan, ZZ	1
Mercieca, K	1
Drury, B	1
Bhargava, A	1
Fenerty, C	1
Irvine, LE	1
Nassif, PS	1
García Tirado, A	1
Boto de Los Bueis, A	1
Rivas Jara, L	1
Colombo, AF	1
Boito, R	1
Bova, F	1
Greco, S	1
Lucà, R	1
Sellaro, A	1
Rizzuto, G	1
Kumaran, A	1
Husain, R	3
Htoon, HM	1
Aung, T	4
Schaub, F	1
Hoerster, R	1
Schiller, P	1
Felsch, M	1
Kraus, D	1
Zarrouk, M	1
Kirchhof, B	1
Fauser, S	1
Hubert, C	1
Lucidi, V	1
Weerts, J	1
Dili, A	1
Demetter, P	1
Massart, B	1
Komuta, M	1
Navez, J	1
Reding, R	1
Gigot, JF	1
Sempoux, C	1
Klompmaker, S	1
Hackert, T	1
Salvia, R	1
Weiss, M	1
Yamaue, H	2
Zeh, HJ	1
Barenboim, A	1
Lahat, G	1
Geva, R	1
Nachmany, I	1
Nakache, R	1
Goykhman, Y	1
Brazowski, E	1
Rosen, G	1
Isakov, O	1
Wolf, I	1
Klausner, JM	2
Lubezky, N	1
Rabiolo, A	1
Marchese, A	1
Bettin, P	2
Monteduro, D	1
Galasso, M	1
Dolci, MP	1
Di Matteo, F	1
Fiori, M	2
Ciampi, C	1
Bandello, F	1
Swann, FB	1
Singh, S	1
Blake, D	1
John, V	1
Le, C	1
Fullerton, M	1
Margo, C	1
Muddasani, N	1
Wall, J	1
Satija, C	1
Greenberg, E	1
Mancera, N	1
Zurakowski, D	1
Ayyala, RS	1
Kim, JS	3
Kim, HJ	1
Na, KI	1
Kim, YK	1
Park, KH	1
Jeoung, JW	1
Hisaka, T	1
Ishikawa, H	1
Sakai, H	1
Kawahara, R	1
Goto, Y	1
Nomura, Y	1
Yasunaga, M	1
Kinugasa, T	1
Fujita, F	1
Mizobe, T	1
Fukahori, M	1
Miwa, K	1
Nakashima, O	1
Tanigawa, M	1
Naito, Y	1
Tanaka, H	1
Akagi, Y	1
Okuda, K	2
Cabau, M	1
Luc, G	1
Terrebonne, E	1
Belleanne, G	1
Vendrely, V	1
Sa Cunha, A	1
Collet, D	1
Sundaram, V	2
Barsam, A	2
Virgili, G	2
Suh, W	1
Kee, C	1
Bondar', GV	1
Basheev, VKh	1
Zolotukhin, SÉ	1
Sovpel', IV	1
Sovpel', OV	1
Chua, TC	1
Quinn, LE	1
Zhao, J	1
Morris, DL	1
Murphy, CC	1
Incalcaterra, JR	1
Albright, HW	1
Correa, AM	1
Swisher, SG	1
Hofstetter, WL	1
Wong, RK	1
Greene, DP	1
Shield, DR	1
Eberhart, CG	1
Huang, JJ	1
Shayegani, A	1
Kulu, Y	1
Büchler, MW	3
Ulrich, A	1
Kim, EY	1
Yechieli, R	1
Kim, JK	1
Mikkelsen, T	1
Kalkanis, SN	1
Rock, J	1
Rosenblum, M	1
Ryu, S	1
Suzuki, R	1
Susanna, R	2
Dellas, K	1
Buller, J	1
Görtz, GJ	1
Richter, M	1
Höhler, T	1
Arnold, D	1
Dunst, J	1
Zühlke, H	1
Ferrandina, G	1
Ercoli, A	1
Fagotti, A	1
Fanfani, F	1
Gallotta, V	1
Margariti, AP	1
Salerno, MG	1
Chiantera, V	1
Legge, F	1
Macchia, G	1
Morganti, AG	1
Valentini, V	2
Scambia, G	1
Maggiori, L	2
Bretagnol, F	1
Aslam, MI	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Non Inferiority Multicenter Phase III Randomized Trial Comparing Preoperative Chemotherapy Only to Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer (Intergroup FRENCH-GRECCAR- PRODIGE)[NCT03875781]	Phase 3	540 participants (Anticipated)	Interventional	2019-06-05	Recruiting
Dragon III- Phase 2: The Preliminary Efficacy Study of FLOT Versus SOX Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer: Open-label, Randomized Controlled Trial[NCT03636893]	Phase 2	74 participants (Actual)	Interventional	2018-08-24	Completed
Patient Reported Outcomes Following Cancer of the Rectum[NCT04936581]		200 participants (Anticipated)	Observational	2021-09-01	Recruiting
Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952]		537 participants (Anticipated)	Interventional	2023-05-01	Recruiting
A Prospective,Single-center,Randomized,Controlled Phase III Clinical Study Comparing Efficacy and Safety of Intraoperative Chemotherapy With 5-Fluorouracil Plus Curative Resection Versus Surgery Alone for Patients With Colorectal Cancer[NCT01465451]	Phase 3	695 participants (Actual)	Interventional	2011-03-31	Active, not recruiting
Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.[NCT02834559]	Phase 3	326 participants (Actual)	Interventional	2016-10-27	Completed
Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Treatment in Encapsulated Blebs: a 12-month Prospective Study[NCT01887223]	Phase 2	40 participants (Actual)	Interventional	2010-05-31	Completed
The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients[NCT01334593]		25 participants (Actual)	Observational	2011-08-31	Completed
Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127]	Phase 2	181 participants (Actual)	Interventional	2006-10-31	Completed
Assessment of Cardiorespiratory Fitness and Lung Function in Lung Cancer Patients Undergoing Neoadjuvant Cancer Therapy and Role of Prehabilitation in Preventing Associated Decline[NCT05636969]		25 participants (Anticipated)	Observational	2023-02-01	Not yet recruiting
A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum[NCT00145769]	Phase 3	326 participants (Actual)	Interventional	2001-07-31	Completed
Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction After Sphincter-preserving Surgery Among Rectal Cancer Patients[NCT03569488]		1,100 participants (Anticipated)	Observational	2020-01-24	Recruiting
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212]	Phase 3	456 participants (Anticipated)	Interventional	2019-10-22	Recruiting
Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Chinese Primary Angle Closure Glaucoma[NCT02964676]		246 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]	Phase 2	8 participants (Actual)	Interventional	2012-04-30	Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596]		264 participants (Actual)	Interventional	2017-01-31	Completed
Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823]	Phase 2	9 participants (Actual)	Interventional	2007-06-30	Terminated (stopped due to Poor accrual.)
Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer[NCT02498353]		100 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946]		46 participants (Actual)	Observational	2009-05-31	Completed
Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473]		200 participants (Actual)	Interventional	2011-08-31	Active, not recruiting
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694]	Phase 3	49 participants (Actual)	Interventional	2019-05-11	Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.)
A Phase III, Multi-institutional Randomised Trial Comparing Neoadjuvant Chemoradiotherapy (NARCT) and Total Neoadjuvant Therapy (TNT) in Patients With T3 (a/b/c) Rectal Cancer[NCT06097416]	Phase 3	100 participants (Anticipated)	Interventional	2024-10-31	Not yet recruiting
A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.[NCT00795301]	Phase 2	74 participants	Interventional	2008-07-31	Active, not recruiting
Retrospective Study Comparing Neoadjuvent Short Course of Radiotherapy to Conventional Chemoradiation in Cancer Rectum[NCT04814784]		48 participants (Anticipated)	Observational	2021-03-31	Not yet recruiting
Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809]		402 participants (Anticipated)	Observational [Patient Registry]	2023-01-01	Not yet recruiting
Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group[NCT02363374]	Phase 2	311 participants (Actual)	Interventional	2015-03-25	Completed
"Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"[NCT03001362]		48 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686]	Phase 2	60 participants (Anticipated)	Interventional	2009-01-31	Active, not recruiting
Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli[NCT04103567]		220 participants (Anticipated)	Interventional	2020-01-14	Recruiting
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405]		97 participants (Actual)	Interventional	2016-10-31	Terminated (stopped due to Withdrawal of analysis study Partner.)
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710]	Phase 2	57 participants (Actual)	Interventional	2004-06-30	Completed
Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial[NCT03465982]		340 participants (Anticipated)	Interventional	2018-06-05	Recruiting
Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer[NCT06114420]		500 participants (Anticipated)	Observational	2023-01-30	Recruiting
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866]		58 participants (Anticipated)	Observational	2022-01-01	Enrolling by invitation
KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191]	Phase 3	358 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867]	Phase 1	0 participants (Actual)	Interventional	2017-03-31	Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened)
Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147]	Phase 2	25 participants (Actual)	Interventional	2011-10-31	Completed
Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2011-01-12	Completed
Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544]	Phase 1	24 participants (Actual)	Interventional	2011-01-31	Completed
A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842]	Phase 2	0 participants (Actual)	Interventional	2017-10-30	Withdrawn (stopped due to non-accrual)
BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410]	Phase 2	60 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly[NCT02992886]	Phase 2	68 participants (Actual)	Interventional	2016-09-30	Completed
FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY[NCT00002523]	Phase 3	1,011 participants (Actual)	Interventional	1993-04-30	Completed
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer[NCT04301557]	Phase 2	25 participants (Anticipated)	Interventional	2020-07-31	Recruiting
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326]	Phase 2	21 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Resource-Sparing Curative Treatment for Rectal Cancer[NCT01459328]	Phase 3	350 participants (Anticipated)	Interventional	2009-09-30	Recruiting
Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052]	Phase 3	240 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618]	Phase 2	41 participants (Actual)	Interventional	2014-07-05	Completed
Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After Ivor-Lewis Esophagectomy. Pilot Study.[NCT02432794]		44 participants (Actual)	Interventional	2015-05-31	Completed
Intermediate Term Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin c in Trabeculectomy Surgery.[NCT00346489]	Phase 4	70 participants	Interventional	2004-09-30	Completed
Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy[NCT03035071]		26 participants (Actual)	Interventional	2010-05-01	Completed
A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123]	Phase 3	301 participants (Actual)	Interventional	2010-04-30	Completed
An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379]	Phase 3	300 participants (Anticipated)	Interventional	2012-05-31	Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.)
[NCT00000122]	Phase 3	0 participants	Interventional	1985-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.

Safety of Respective Neoadjuvant Therapies.

Intervention	Participants (Count of Participants)
Radiochemotherapy	22
Chemotherapy	7

Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up

HRQOL and Swallowing Function

Intervention	Participants (Count of Participants)
Radiochemotherapy	79
Chemotherapy	81

The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up

All-cause Mortality

Change in Tumor Size From Pretreatment to Preoperative CT Scan

Intervention	units on a scale (Mean)
	Mean global QoL	Dysphagia score all
Chemotherapy	69	31
Radiochemotherapy	67	27

Intervention	participants (Number)
Arm 1 - Wildtype	0
Arm 2 K-Ras 12/13 Codon Mutation	0

-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)

Effect of Preoperative Chemotherapy on Tumor Size

Intervention	percentage of change of longest diameter (Median)
Arm 1 - Wildtype	-23.8
Arm 2 K-Ras 12/13 Codon Mutation	-14.3

Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)

Major Postoperative Complication Rate

Intervention	participants (Number)
Arm 1 - Wildtype	4
Arm 2 K-Ras 12/13 Codon Mutation	2

Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery

Postoperative Complication Rate

Intervention	percentage of participants (Number)
Arm 1 - Wildtype	25
Arm 2 K-Ras 12/13 Codon Mutation	0

Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery

Histologic Hepatic Toxicity at Surgery

Nonalcoholic Steatohepatitis Score (0-3)

Intervention	percentage of participants (Number)
Arm 1 - Wildtype	25
Arm 2 K-Ras 12/13 Codon Mutation	0

Intervention	participants (Number)
	Not reported on pathology report	Mild	Aborted surgery	None
Arm 1 - Wildtype	1	1	1	1
Arm 2 K-Ras 12/13 Codon Mutation	0	0	0	1

"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)

Postoperative Recurrence Patterns

Number of Participants Experienced Dose Limited Toxicity

Intervention	participants (Number)
	Not reported on pathology report	Aborted surgery	Score 0
Arm 1 - Wildtype	3	1	0
Arm 2 K-Ras 12/13 Codon Mutation	0	0	1

Intervention	participants (Number)
	Liver only	Distant disease
Arm 1 - Wildtype	0	1
Arm 2 K-Ras 12/13 Codon Mutation	0	0

Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment

Intervention	participants (Number)
1000mg	0
1200mg	1
1350mg	1
1500mg	0
1650mg	1

Article	Year
Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review. The American journal of case reports, 2020, Jan-05, Volume: 21 Topics: Adenocarcinoma; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Appendiceal	2020
Needling after trabeculectomy - does augmentation by anti-metabolites provide better outcomes and is Mitomycin C better than 5-Fluoruracil? A systematic review with network meta-analyses. Acta ophthalmologica, 2020, Volume: 98, Issue:7 Topics: Fluorouracil; Glaucoma; Humans; Immunosuppressive Agents; Intraocular Pressure; Mitomycin; Network M	2020
[Role of Intraoperative Indirect Channelography in Glaucoma Stent Implantation]. Klinische Monatsblatter fur Augenheilkunde, 2017, Volume: 234, Issue:11 Topics: Administration, Ophthalmic; Aged, 80 and over; Bevacizumab; Combined Modality Therapy; Female; Fluor	2017
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. The Cochrane database of systematic reviews, 2013, Jan-31, Issue:1 Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Intravitreal Injections; Postoperative Complica	2013
[Radiotherapy-associated morbidity and mortality in rectal surgery]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2013, Volume: 84, Issue:11 Topics: Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Guideline Adherence; Humans; Infusio	2013
[Operative techniques for surgical treatment of primary and recurrent pterygia]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2010, Volume: 107, Issue:6 Topics: Antimetabolites, Antineoplastic; Astigmatism; Biological Dressings; Combined Modality Therapy; Conju	2010
Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. The Cochrane database of systematic reviews, 2010, Jul-07, Issue:7 Topics: Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Injections, Intraocular; Postoperative Complica	2010
Anti--vascular endothelial growth factor therapy in glaucoma filtration surgery. American journal of ophthalmology, 2011, Volume: 152, Issue:1 Topics: Alkylating Agents; Angiogenesis Inhibitors; Filtering Surgery; Fluorouracil; Glaucoma, Open-Angle; H	2011
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. The Annals of thoracic surgery, 2012, Volume: 93, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia	2012
Deep sclerectomy. Developments in ophthalmology, 2012, Volume: 50 Topics: Conjunctiva; Fibrosis; Fluorouracil; Follow-Up Studies; Glaucoma; Humans; Immunosuppressive Agents;	2012
[Pancreatic cancer. The relative importance of neoadjuvant therapy]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2003, Volume: 74, Issue:3 Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Case-Control Studies; Child; Ci	2003
[Modulation of wound healing in filtration surgery for glaucoma]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2003, Volume: 100, Issue:4 Topics: Adolescent; Adult; Age Factors; Alkylating Agents; Animals; Antimetabolites; Child; Filtering Surger	2003
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC). Surgical endoscopy, 2003, Volume: 17, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula	2003
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. The Annals of thoracic surgery, 2004, Volume: 78, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel	2004
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Annals of surgery, 2006, Volume: 243, Issue:2 Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hum	2006
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites,	2006
[Complications of surgical resection of esophageal cancer]. Cirugia espanola, 2006, Volume: 80, Issue:6 Topics: Adenocarcinoma; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Endosc	2006
[Wound healing modulation in glaucoma surgery]. Journal francais d'ophtalmologie, 2007, Volume: 30, Issue:6 Topics: Adult; Animals; Cataract Extraction; Child; Cicatrix; Eye Diseases; Filtering Surgery; Fluorouracil;	2007
Salvage oesophagectomy after local failure of definitive chemoradiotherapy. The British journal of surgery, 2007, Volume: 94, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagea	2007
Total mesorectal excision and management of rectal cancer. Expert review of anticancer therapy, 2007, Volume: 7, Issue:10 Topics: Adenocarcinoma; Anastomosis, Surgical; Antineoplastic Agents; Combined Modality Therapy; Disease Man	2007
[5-fluorouracil in the treatment and prevention of acute pancreatitis]. Vestnik khirurgii imeni I. I. Grekova, 1982, Volume: 129, Issue:8 Topics: Acute Disease; Animals; Depression, Chemical; DNA; Fluorouracil; Humans; Infusions, Intra-Arterial;	1982
Treatment of skin cancer using multiple modalities. Journal of the American Academy of Dermatology, 1982, Volume: 7, Issue:2 Topics: Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cryosurgery; Electrosurgery; Female; F	1982
[Current perspectives in the treatment of epidermoid cancer of the esophagus]. Presse medicale (Paris, France : 1983), 1995, Jun-24, Volume: 24, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali	1995
Trabeculectomy with intraoperative sponge 5-fluorouracil in Afro-Caribbeans. The British journal of ophthalmology, 1997, Volume: 81, Issue:7 Topics: Administration, Topical; Antimetabolites; Black People; Case-Control Studies; Female; Fluorouracil;	1997
A major review of antimetabolites in glaucoma therapy. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 1999, Volume: 213, Issue:4 Topics: Antimetabolites; Cytarabine; Filtering Surgery; Fluorouracil; Glaucoma; Humans; Mitomycin; Ophthalmi	1999
[The use of antimetabolites in the treatment of glaucoma]. Oftalmologia (Bucharest, Romania : 1990), 1999, Volume: 48, Issue:3 Topics: Antimetabolites; Chemotherapy, Adjuvant; Fluorouracil; Glaucoma; Humans; Intraoperative Care; Mitomy	1999
Abdominal surgery (second of three parts). The New England journal of medicine, 1975, Oct-30, Volume: 293, Issue:18 Topics: Abdomen; Acute Disease; Anus Diseases; Appendectomy; Appendicitis; Appendix; Carcinoembryonic Antige	1975
[Use of drugs inhibiting fibrosis after trabeculectomy]. Harefuah, 1992, Nov-15, Volume: 123, Issue:10 Topics: Adrenal Cortex Hormones; Aminopropionitrile; Fibrosis; Fluorouracil; Humans; Mitomycin; Postoperativ	1992
Encapsulated filtering bleb. A selective review--new deductions. Eye (London, England), 1992, Volume: 6 ( Pt 4) Topics: Animals; Blister; Cicatrix; Conjunctival Diseases; Fibroblasts; Fluorouracil; Glaucoma; Humans; Post	1992
[Prevention of acute postoperative pancreatitis]. Klinicheskaia khirurgiia, 1990, Issue:11 Topics: Acute Disease; Endopeptidases; Fluorouracil; Humans; Pancreatitis; Postoperative Complications	1990
[5-Fluorouracil and trabeculectomy. A trial of low doses]. Journal francais d'ophtalmologie, 1990, Volume: 13, Issue:4 Topics: Female; Fluorouracil; Humans; Injections; Male; Middle Aged; Postoperative Complications; Trabeculec	1990
Status of ischemic therapy for hepatic tumors. The Surgical clinics of North America, 1989, Volume: 69, Issue:2 Topics: Combined Modality Therapy; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Postoper	1989
[Prevention of eye scarring by 5-fluorouracil]. Harefuah, 1987, Nov-15, Volume: 113, Issue:10 Topics: Animals; Cicatrix; Disease Models, Animal; Eye; Fluorouracil; Glaucoma; Humans; Postoperative Compli	1987
Controversies in the management of potentially curable breast cancer. Surgery annual, 1974, Volume: 6 Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph	1974
Management of cancer of the colon. The Surgical clinics of North America, 1974, Volume: 54, Issue:3 Topics: Colitis, Ulcerative; Colon; Colonic Diseases; Colonic Neoplasms; Diagnostic Errors; Fluorouracil; Hu	1974

fluorouracil and Complication, Postoperative